Alendronate sodium and vitamin D in postmenopausal osteoporosis

A systematic review

Keywords: osteoporosis, postmenopause, alendronate, vitamin D, bone recovery


Aim: to evaluate the effectiveness of using the combined therapy of sodium alendronate and vitamin D on bone metabolism in women undergoing postmenopausal osteoporosis. 
Methods: this is a systematic review. The studies included were Randomized Controlled Trials (RCT) indexed in the BVS, ISI Web of Science, PubMed, SciELO, ScienceDirect and Scopus Databases which compared the association of sodium alendronate and vitamin D to monotherapy of sodium alendronate. 
Results: a total of six RCT met the criteria to be included in this study, comprising a total of 4164 participants and their respective data. The studies evaluated different domains of bone metabolism, such as serum levels of vitamin D, parathyroid hormone, bone mineral density and bone turnover markers. Combination therapy produced significant improvement in bone metabolic markers. 
Conclusion: combined therapy of sodium alendronate with vitamin D promotes improved bone metabolism in women with postmenopausal osteoporosis.


Download data is not yet available.

Author Biographies

José Reginaldo Alves de Queiroz Júnior, Universidade Federal de Pernambuco (UFPE), Centro de Ciências Médicas, Recife, PE, Brasil.

Graduando em Medicina pela Universidade Federal de Pernambuco (UFPE), em Recife, PE, Brasil.

Jarson Pedro da Costa Pereira, Universidade Federal de Pernambuco (UFPE), Hospital das Clínicas, Recife, PE, Brasil.

Mestrando em Nutrição e Saúde Pública pela Universidade Federal de Pernambuco (UFPE), em Recife, PE, Brasil.

Leonardo Lucas Pires, Universidade Potiguar (UnP), Departamento de Ciências Médicas, Natal, RN, Brasil.

Graduando em Medicina pela Universidade Potiguar (UnP), em Natal, RN, Brasil. 

Carina Scanoni Maia, Universidade Federal de Pernambuco (UFPE), Departamento de Histologia e Embriologia, Recife, PE, Brasil.

Doutora em Biociência Animal pela Universidade Federal Rural de Pernambuco (UFRPE), em Recife, PE, Brasil; Professora da Universidade Federal de Pernambuco (UFPE), em Recife, PE, Brasil.


Radominski SC, Bernardo W, Paula AP, Albergaria B, Moreira C, Fernandes CE, et al. Diretrizes brasileiras para o diagnóstico e tratamento da osteoporose em mulheres na pós-‐menopausa. Rev Bras Reumatol. 2017;57:452-66.

Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatmentof osteoporosis. Osteoporos Int. 2014;25:2359.

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001; 285:785-95.

Lazaretti-Castro M, Eis SR, Marques Neto JF. A prevenção da osteoporose levada a sério: uma necessidade nacional. Arq Bras Endrocrinol Metab. 2008;52(4):712-3.

Mabey T, Honsawek S. Role of Vitamin D in osteoarthritis: molecular, cellular, and clinical perspectives. Int J Endocrinol. 2015;2015:1-14.

Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-81.

Narula K, Tauseef M, Ahmad I, Agarwal K, Ashok A, Anjana A. Vitamin D deficiency among postmenopausal women with osteoporosis. J Clin Diagn Res. 2013;7:336-8.

Sahota O. Osteoporosis and the role of vitamin D and calcium-vitamin D deficiency, vitamin D insufficiency and vitamin D sufficiency. Age Ageing. 2000;29:301-4.

Rosen CJ. The Epidemiology and pathogenesis of osteoporosis [Updated 2014 Jan 10]. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext South Dartmouth (MA): MDText com, Inc. 2014; 2000: Available from:

Agnusdei D, Crepaldi G, Isaia G, et al. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss. Calcif Tissue Int. 1997;61(2):142-147.

Kocijan R, Klaushofer K, Misof BM. Osteoporosis therapeutics 2020, Berlin, Heidelberg: Springer Berlin Heidelberg; 2020.

Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med. 2010;362(19):1761-71.

Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone. 2007;40(5): 1238-43.

Higgins JP, Thomas J, Chandler J et al., editors. Cochrane handbook for systematic reviews of interventions. Chichester (UK): John Wiley & Sons; 2019.

Roux C, Binkley N, Boonen S, et al. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int. 2014;94(2):153-7.

Kim KJ, Min YK, Koh JM, et al. Efficacy and safety of weekly alendronate plus vitamin D₃ 5600 IU versus weekly alendronate alone in korean osteoporotic women: 16-week randomized trial. Yonsei Med J. 2014;55(3):715-24.

Olmos JM, Hernández JL, Llorca J, et al. Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate. J Clin Endocrinol Metab. 2012;97(12):4491–7.

Orimo H, Nakamura T, Fukunaga M, et al. Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the japanese osteoporosis intervention trial (JOINT) - 02. Curr Med Res Opin. 2011;27(6):1273-84.

Binkley N, Ringe JD, Reed JI, Ljunggren O, Holick MF, Minne HW, Liu M, Lamotta A, West JA, Santora AC. Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial. Bone. 2009;44(4):639-47.

Recker R, Lips P, Felsenberg D, et al. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. Curr Med Res Opin. 2006;22(9):1745-55.

Mata PR, Martins PA, Brito LG, Ramos MMP, Santos Junior, MC. Tratamento farmacológico para a osteoporose. Geriatrics, Gerontology and Aging. 2012;6(4):422–31.

Benjamin B, Benjamin MA, Swe M, Sugathan S. Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis. Osteoporosis and Sarcopenia. 2016;2:77-81.

Drieling RL, LaCroix AZ, Beresford SAA, Boudreau DM, Kooperberg C, Chlebowski RT, et al. Long-Term oral bisphosphonate therapy and fractures in older women: the women’s health initiative. J Am Geriatr Soc. 2017;65:1924-31.

Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. JMCP. 2009;15:728-40.

Barrett-Connor E, Wade SW, Do TP, Satram-Hoang S, Stewart R, Gao G, et al. Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE USTM. Osteoporos Int. 2012;23:733-41.

Leib ES, Lewiecki EM, Binkley N, Hamdy RC. Official positions of the international society for clinical densitometry. J Clin Densitom. 2004;7:1-6.

Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. The Lancet Diabetes & Endocrinology. 2017;5:908-23.

Vasikaran SD. Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem. 2001;38(6):608-623.

Horwitz MJ, Tedesco MB, Sereika SM, Syed MA, Garcia-Ocaña A, Bisello A, et al. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J Bone Miner Res. 2005;20:1792-1803.

Cândido F, Bressan J. Vitamin D: Link between Osteoporosis, obesity, and diabetes? IJMS. 2014;15:6569-91.

Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293:2257.

How to Cite
Júnior, J. R. A. de Q., Pereira, J. P. da C., Pires, L. L., & Maia, C. S. (2022). Alendronate sodium and vitamin D in postmenopausal osteoporosis: A systematic review. Scientia Medica, 32(1), e42267.
Systematic Review and Meta-Analysis